These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32886565)

  • 1. Advanced engineering of third-generation lysins and formulation strategies for clinical applications.
    De Maesschalck V; Gutiérrez D; Paeshuyse J; Lavigne R; Briers Y
    Crit Rev Microbiol; 2020 Sep; 46(5):548-564. PubMed ID: 32886565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence-Function Relationships in Phage-Encoded Bacterial Cell Wall Lytic Enzymes and Their Implications for Phage-Derived Product Design.
    Vázquez R; García E; García P
    J Virol; 2021 Jun; 95(14):e0032121. PubMed ID: 33883227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriophage-derived endolysins to target gram-negative bacteria.
    Lai WCB; Chen X; Ho MKY; Xia J; Leung SSY
    Int J Pharm; 2020 Nov; 589():119833. PubMed ID: 32877733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research Progress on Strategies for Improving the Enzyme Properties of Bacteriophage Endolysins.
    Wang Y; Wang X; Liu X; Lin B
    J Microbiol Biotechnol; 2024 Jun; 34(6):1189-1196. PubMed ID: 38693045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacteriophage endolysins as a novel class of antibacterial agents.
    Borysowski J; Weber-Dabrowska B; Górski A
    Exp Biol Med (Maywood); 2006 Apr; 231(4):366-77. PubMed ID: 16565432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad Bactericidal Activity of the
    Antonova NP; Vasina DV; Lendel AM; Usachev EV; Makarov VV; Gintsburg AL; Tkachuk AP; Gushchin VA
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30901901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic biology of modular endolysins.
    Gerstmans H; Criel B; Briers Y
    Biotechnol Adv; 2018; 36(3):624-640. PubMed ID: 29248682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering a Lysin with Intrinsic Antibacterial Activity (LysMK34) by Cecropin A Fusion Enhances Its Antibacterial Properties against Acinetobacter baumannii.
    Abdelkader K; Gutiérrez D; Tamés-Caunedo H; Ruas-Madiedo P; Safaan A; Khairalla AS; Gaber Y; Dishisha T; Briers Y
    Appl Environ Microbiol; 2022 Jan; 88(1):e0151521. PubMed ID: 34669452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bacteriophage lysins: progress and perspective--a review].
    Wang Y; Lu C
    Wei Sheng Wu Xue Bao; 2009 Oct; 49(10):1277-81. PubMed ID: 20069871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation of Phage Lysins That Effectively Kill Pseudomonas aeruginosa in Mouse Models of Lung and Skin Infection.
    Raz A; Serrano A; Hernandez A; Euler CW; Fischetti VA
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gram-negative endolysins: overcoming the outer membrane obstacle.
    Sisson HM; Jackson SA; Fagerlund RD; Warring SL; Fineran PC
    Curr Opin Microbiol; 2024 Apr; 78():102433. PubMed ID: 38350268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phage lysins for intestinal microbiome modulation: current challenges and enabling techniques.
    Pottie I; Vázquez Fernández R; Van de Wiele T; Briers Y
    Gut Microbes; 2024; 16(1):2387144. PubMed ID: 39106212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LysSAP26, a New Recombinant Phage Endolysin with a Broad Spectrum Antibacterial Activity.
    Kim S; Jin JS; Choi YJ; Kim J
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33238548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy.
    Oliveira H; São-José C; Azeredo J
    Viruses; 2018 May; 10(6):. PubMed ID: 29844287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteriophage endolysins against gram-positive bacteria, an overview on the clinical development and recent advances on the delivery and formulation strategies.
    Ho MKY; Zhang P; Chen X; Xia J; Leung SSY
    Crit Rev Microbiol; 2022 May; 48(3):303-326. PubMed ID: 34478359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant bacteriophage lysins as antibacterials.
    Fenton M; Ross P; McAuliffe O; O'Mahony J; Coffey A
    Bioeng Bugs; 2010; 1(1):9-16. PubMed ID: 21327123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antibacterial activity of E. coli bacteriophage lysin lysep3 is enhanced by fusing the Bacillus amyloliquefaciens bacteriophage endolysin binding domain D8 to the C-terminal region.
    Wang S; Gu J; Lv M; Guo Z; Yan G; Yu L; Du C; Feng X; Han W; Sun C; Lei L
    J Microbiol; 2017 May; 55(5):403-408. PubMed ID: 28124780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysins breaking down the walls of Gram-negative bacteria, no longer a no-go.
    Gutiérrez D; Briers Y
    Curr Opin Biotechnol; 2021 Apr; 68():15-22. PubMed ID: 33053478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phages and engineered lysins as an effective tool to combat Gram-negative foodborne pathogens.
    Kocot AM; Briers Y; Plotka M
    Compr Rev Food Sci Food Saf; 2023 May; 22(3):2235-2266. PubMed ID: 37009835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting phage receptor binding proteins to enable endolysins to kill Gram-negative bacteria.
    Zampara A; Sørensen MCH; Grimon D; Antenucci F; Vitt AR; Bortolaia V; Briers Y; Brøndsted L
    Sci Rep; 2020 Jul; 10(1):12087. PubMed ID: 32694655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.